United States securities and exchange commission logo

                          August 17, 2021

       Marvin White
       President and Chief Executive Officer
       Aptevo Therapeutics Inc.
       2401 4th Avenue, Suite 1050
       Seattle, WA 98121

                                                        Re: Aptevo Therapeutics
Statement on Form S-3
                                                            Filed August 12,
                                                            File No. 333-258758

       Dear Mr. White:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Margaret
Schwartz at 202-551-7153 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Sean M. Donahue, Esq.